Doctors track safety of new psoriasis drug in real patients
NCT ID NCT05670821
Summary
This study monitored patients in Japan who were newly prescribed the intravenous drug spesolimab for severe flare-ups of generalized pustular psoriasis (GPP). The main goal was to track any side effects that occurred in a real-world setting, outside of a controlled clinical trial. Researchers also observed how the disease behaved in these patients after they started the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan
Conditions
Explore the condition pages connected to this study.